Karyopharm posts a $2.32 per share loss for Q2 while revenue of $33.43M exceeds forecasts by $1.21M.
Karyopharm Therapeutics reported a Q2 GAAP loss of $2.32 per share, missing estimates by $0.90. The company’s revenue reached $33.43M, down 11.9% year-over-year but beating expectations by $1.21M.
The prior-year quarter saw higher revenue, though specific figures were not disclosed. Analysts had anticipated a narrower loss, making the earnings miss notable despite the revenue beat.
As of June 30, 2026, the company’s cash, cash equivalents, restricted cash, and investments totaled $65.4 million, providing a financial cushion amid ongoing operations.